The primary goal of The Ohio State University / M.D. Anderson Thyroid Cancer SPORE is to improve the outcomes and lives of patients with thyroid cancer by identifying genetically """"""""at-risk"""""""" individuals allowing for early diagnosis and prediction of tumor behavior, developing new approaches to minimize side effects of treatments, and developing better biomarkers and treatment options for progressive metastatic disease. Several factors support the importance of applying these efforts to thyroid cancer: 1) Thyroid cancer incidence is rising at the fastest rate of all malignancies in the United States and worldwide;it s now the 5th most common malignancy in women and 11th most common in men. 2) Thyroid cancer typically takes an indolent course, thus with the increasing incidence there is an ever enlarging population of individuals (-500,000) surviving long term, many of whom suffer from lifelong effects of initial therapy. 3) For patients with more aggressive forms of thyroid cancer, such as medullary cancer (MTC), there exist no curative therapies or biomarkers that accurately predict outcome from disease or response to particular treatments thereby limiting efforts to individualize therapeutic intensity. In order to achieve our goals, this SPORE application proposes to support a multi-institutional team of experienced investigators from two of the leading institutions in the field with a history of collaborative clinical trials. We have chosen t focus on critical areas of need for rapid translation into clinical practice for thyroid cancer patients with the following four Projects supported by outstanding Cores: 1) Low-penetrance genes in the predisposition to papillary thyroid carcinoma;2) Biomarker discovery and personalized intervention of radioiodine induced salivary gland damage in thyroid cancer patients;3) Developing combination therapies for Medullary Thyroid Cancer;and 4) Development and validation of novel circulating medullary thyroid cancer markers. Through these translational Projects, as well as Career Developmental and Developmental Research Programs, we aim to impact on critical areas of need in thyroid cancer clinical management for all forms of thyroid cancer.
Thyroid cancer incidence is rising. Key issues in clinical care related to predictive testing for more aggressive disease, improving survivorship as many patients live for decades after their diagnosis, improving treatment for patients with aggressive forms of thyroid cancer and improving detection and monitoring of metastases This SPORE addresses these critical areas to improve the outcomes of patients with thyroid cancer.
|Cote, Gilbert J; Evers, Caitlin; Hu, Mimi I et al. (2017) Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102:3591-3599|
|Gudmundsson, Julius; Thorleifsson, Gudmar; Sigurdsson, Jon K et al. (2017) A genome-wide association study yields five novel thyroid cancer risk loci. Nat Commun 8:14517|
|Rossfeld, Kara K; Justiniano, Steven E; Ding, Haiming et al. (2017) Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model. J Clin Endocrinol Metab 102:3268-3277|
|El Naofal, Maha; Kim, Adriel; Yon, Hui Yi et al. (2017) Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma. Ann Clin Lab Sci 47:523-528|
|Valenciaga, Anisley; Grubbs, Elizabeth G; Porter, Kyle et al. (2017) Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer. Thyroid 27:1523-1533|
|Nabhan, F; Porter, K; Senter, L et al. (2017) Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients. J Endocrinol Invest 40:1015-1021|
|Sandulache, Vlad C; Williams, Michelle D; Lai, Stephen Y et al. (2017) Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid 27:81-87|
|Nabhan, Fadi; Ringel, Matthew D (2017) Thyroid nodules and cancer management guidelines: comparisons and controversies. Endocr Relat Cancer 24:R13-R26|
|Bagheri-Yarmand, Rozita; Williams, Michelle D; Grubbs, Elizabeth G et al. (2017) ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer. J Clin Endocrinol Metab 102:933-941|
|Wang, Yanqiang; He, Huiling; Li, Wei et al. (2017) MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus. Proc Natl Acad Sci U S A 114:474-479|
Showing the most recent 10 out of 37 publications